IP.ADJUTOR
Information on this blog is being shared only for the purpose of creating legal awareness in public at large, especially in the field of Intellectual Property Right. As there may be possibility of error, omission or mistake in legal interpretation on the contents of this blog, it should not be treated as substitute for legal advise.
Wednesday, September 17, 2025
BASE SE Vs. Deputy Controller of Patents and Designs
UPL Limited Vs. Union of India
Novartis AG Vs. Controller of Patents -Manmeet Pritam Singh
Fact: Novartis AG is the holder of Indian Patent No. 414518, which was granted after dismissal of several pre-grant oppositions. Post-grant, various pharmaceutical parties filed oppositions challenging the validity of the patent on the grounds of lack of inventive step and violation of Section 3(d) of the Patents Act, 1970. The patent grant was followed by procedural battles—opponents submitted further expert evidence through affidavits and Novartis responded with requests to file rebuttal evidence. This procedural exchange continued until a timeline was set by a prior High Court order to ensure expeditious proceedings in the post-grant opposition process.
Procedural Detail: Novartis filed its patent application in 2007 and received grant in December 2022. Following this, opponents filed post-grant oppositions under Section 25(2) of the Patents Act. Opponents submitted expert affidavits under Rule 60 of the Patent Rules, and Novartis objected, but the Controller admitted the evidence. Novartis sought an opportunity to file rebuttal evidence, which was initially rejected by the Controller. Novartis challenged this by filing writ petitions contesting the denial and the procedure followed. The High Court set aside earlier orders and allowed Novartis to file rebuttal evidence, ordered a new Controller for the matter and demanded that the process move forward under strict timelines. The parties complied with the directions—Novartis filed rebuttal evidence, the Opposition Board issued a fresh recommendation, and hearings were scheduled by the Controller. However, Novartis sought cross-examination of the opponents’ expert witnesses after having already filed rebuttal evidence and after the timeline for such applications had passed, leading to the present dispute over whether this belated request was maintainable.
Dispute: At the heart of the case is whether Novartis retained a right to seek cross-examination of expert witnesses after initially omitting to request it and electing instead to file rebuttal evidence. Novartis argued that the right to cross-examine arises as a matter of natural justice and does not get extinguished by not seeking it at the earliest stage. Respondents, including various pharmaceutical companies, opposed this position stating Novartis had multiple opportunities to make such a request and by not doing so had waived the right or was barred on grounds of delay and procedural abuse. They asserted that permitting the request at this stage would undermine the Court’s order for expeditious conclusion and render the previous proceedings futile.
Detailed Reasoning Including Judgements: Justice Manmeet Pritam Singh Arora systematically examined the sequence of events and arguments by both sides. The judgment discussed key procedural stages, including evidentiary filings, objections, hearings, and previous High Court interventions that set guidelines for timely and fair conduct. The Court considered if principles of natural justice demanded allowance of cross-examination at any stage, referencing several judgements such as Onyx Therapeutics v. Union of India (2019 SCC OnLine Del 7259, 11881) and Natco Pharma Ltd. v. Union of India (2019 SCC OnLine Cal 1609), which asserted cross-examination as a substantive right under Section 79 of the Patents Act. The Court, however, clarified that such a right must be exercised promptly, preferably at the time the expert evidence is admitted, to avoid unwarranted delay and disruption of proceedings.
The Court differentiated the facts of Onyx Therapeutics, where the patentee made immediate requests for cross-examination, from Novartis’s situation, where the request came much later after the right of rebuttal was specifically claimed and allowed, thereby satisfying natural justice. It is reasoned that failure to timely exercise the right, especially after a conscious election to file rebuttal evidence, not only constituted waiver but also operated as estoppel. The Court declared that the stage for seeking cross-examination ended when the Controller decided on the admissibility of evidence. Delay or tactical withholding of request cannot be used to reset the process or frustrate the timeline set by earlier judicial orders.
The Court addressed whether denial of cross-examination at a late stage constituted breach of natural justice and held it did not, as adequate opportunity for rebuttal was allowed and utilized. Judicial directions for expeditious disposal, and the procedural structure of patent oppositions—where evidence is first submitted and reviewed by an Opposition Board—were emphasized as safeguards for fairness and efficiency. The Court found that Novartis’s conduct in abstaining from hearings further reinforced procedural abandonment, and disallowed late assertions of rights which had already been considered and exhausted through the judicial process.
Decision: Justice Arora dismissed the writ petitions, upholding the Controller’s refusal to entertain the belated cross-examination request. The Court found that Novartis had waived its procedural right to cross-examination by electing to file rebuttal evidence and not seeking cross-examination at the time evidence was admitted. No procedural or substantive violation of natural justice had taken place. The efforts and timelines set by the Opposition Board and the earlier orders of the Court were protected against disruption through dilatory tactics. All pending applications were disposed of, confirming that parties must exercise their procedural rights in a timely and diligent manner, respecting guidelines laid down by judicial proceedings and statutory rules.
Disclaimer: The information shared here is intended to serve the public interest by offering insights and perspectives. However, readers are advised to exercise their own discretion when interpreting and applying this information. The content herein is subjective and may contain errors in perception, interpretation, and presentation.
Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
Monday, September 15, 2025
Nupur Mehta Vs Bennett Coleman
Burberry Ltd Vs Megastar Shipping Pte Ltd
Exotic Mile Vs. Imagine Marketing Pvt Ltd
Sunday, September 14, 2025
Aishwarya Rai Bachchan Vs Aishwaryaworld.com
Abhishek Bachchan Vs The Bollywood Tee Shop
Saturday, September 13, 2025
Tractors and Farm Equipment Ltd. Vs. Standard Corporation India Ltd
New Bharat Overseas Vs Bhagwati Lacto Vegetarian Exports Pvt. Ltd
Blog Archive
- September 2025 (54)
- August 2025 (103)
- July 2025 (95)
- June 2025 (93)
- May 2025 (118)
- April 2025 (91)
- March 2025 (148)
- February 2025 (116)
- January 2025 (58)
- October 2024 (8)
- September 2024 (34)
- August 2024 (68)
- July 2024 (39)
- June 2024 (57)
- May 2024 (49)
- April 2024 (6)
- March 2024 (44)
- February 2024 (39)
- January 2024 (21)
- December 2023 (29)
- November 2023 (23)
- October 2023 (27)
- September 2023 (33)
- August 2023 (29)
- July 2023 (29)
- June 2023 (2)
- May 2023 (1)
- April 2023 (5)
- March 2023 (6)
- February 2023 (1)
- November 2022 (17)
- October 2022 (11)
- September 2022 (30)
- August 2022 (46)
- July 2022 (36)
- June 2022 (26)
- October 2020 (1)
- September 2020 (1)
- April 2020 (1)
- March 2020 (1)
- February 2020 (2)
- December 2019 (1)
- September 2019 (3)
- August 2019 (2)
- July 2019 (1)
- June 2019 (2)
- April 2019 (3)
- March 2019 (2)
- February 2019 (2)
- January 2019 (2)
- December 2018 (3)
- November 2018 (1)
- October 2018 (2)
- September 2018 (2)
- August 2018 (8)
- July 2018 (2)
- June 2018 (1)
- May 2018 (41)
- April 2018 (7)
- March 2018 (3)
- February 2018 (4)
- January 2018 (2)
- December 2017 (6)
- November 2017 (4)
- September 2017 (5)
- August 2017 (6)
- July 2017 (1)
- June 2017 (1)
- May 2017 (10)
- April 2017 (16)
- November 2016 (3)
- October 2016 (24)
- March 2015 (2)
- January 2014 (1)
- December 2013 (4)
- October 2013 (2)
- September 2013 (7)
- August 2013 (27)
- May 2013 (7)
- September 2012 (31)
- December 2009 (3)
- September 2009 (1)
- March 2009 (3)
- January 2009 (2)
- December 2008 (1)
Featured Post
WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING
WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING IN ORDER TO PROVE THE TRADEMARK REGISTRA...
-
Species patents following a Markush patent must demonstrate a distinct inventive step Introduction The AstraZeneca AB & Anr. Vs. Intas ...
-
$~ * IN THE HIGH COURT OF DELHI AT NEW DELHI + CS(COMM) 1307/2016 M/S. KHUSHI RAM...
My Blog List
-
किस्सा आसान हो जाऊँ - हर सच से मुँह मोड़कर नादान हो जाऊँ, इतना भी अच्छा नहीं कि गुमनाम हो जाऊँ। आईना सच हीं दिखलाए ये ज़रूरी नहीं, झूठ हूँ इतना नही कि वो ही पहचान हो जाऊँ। हर...2 days ago
-
IPL:Spice In, Nationality Out - I was sitting in my office. It was a hot afternoon. The fan was running slowly and making strange sounds like an old typewriter. Files were lying on my d...4 months ago
-
-
My other Blogging Links
- Ajay Amitabh Suman's Poem and Stories
- Facebook-My Judgments
- Katha Kavita
- Lawyers Club India Articles
- My Indian Kanoon Judgments
- Linkedin Articles
- Speaking Tree
- You Tube-Legal Discussion
- बेनाम कोहड़ा बाजारी -Facebook
- बेनाम कोहड़ा बाजारी -वर्ड प्रेस
- बेनाम कोहड़ा बाजारी-दैनिक जागरण
- बेनाम कोहड़ा बाजारी-नवभारत टाइम्स
- बेनाम कोहड़ा बाजारी-ब्लॉग स्पॉट
- बेनाम कोहड़ा बाजारी-स्पीकिंग ट्री